Pancreatic Cancer: Promises and Failures of Target Therapies

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|11|1|33-38

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.11, Iss.1, 2016-03, pp. : 33-38

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer

By  

BRITISH JOURNAL OF SURGERY, Vol. 102, Iss. 3, 2015-02 ,pp. : 182-193

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies

By Meece Jerry  

Current Medical Research and Opinion, Vol. 23, Iss. 4, 2007-04 ,pp. : 933-944

Informa Healthcare

Access to resources Recommend Favorite

What Else in Gemcitabine-Pretreated Advanced Pancreatic Cancer? An Update of Second Line Therapies

By  

Reviews on Recent Clinical Trials, Vol. 5, Iss. 1, 2010-01 ,pp. : 43-56

Bentham Science Publishers

Access to resources Recommend Favorite

Pancreatic cancer

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 171, Iss. 4, 2014-02 ,pp. : 849-858

John Wiley & Sons Inc

Access to resources Recommend Favorite

Expression of vitamin D receptor as a potential prognostic factor and therapeutic target in pancreatic cancer

By  

HISTOPATHOLOGY, Vol. 67, Iss. 3, 2015-09 ,pp. : 386-397

John Wiley & Sons Inc

Access to resources Recommend Favorite